Genelux Corporation
GNLXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Genelux Corporation focuses on Biotechnology services and products. Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor. At a $110.4M market cap, Genelux Corporation ranks as a micro-cap company within healthcare. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.
Market Cap
$110.4M
Beta
0.56
P/E (TTM)
—
P/E (Fwd)
-3.29
EPS (TTM)
$-0.86
EPS (Fwd)
$-0.74
ROE
-177.9%
ROA
-77.9%
Cash
$18.7M
Total Debt
$2.4M
Free CF
-$15.3M
52W Change
-31.5%
Annual Financials
Cash vs Debt
Where GNLX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, GNLX finished 7.94% below its 150-day moving average ($2.77) and 17.48% below its 200-day moving average ($3.09). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GNLX overbought or oversold?
At the September 3, 2026 close, GNLX's RSI(14) was 45.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $18.7M in cash comfortably exceeding the $2.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$15.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -177.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $11.1M (2022) to $8K (2025), a 100% decline worth watching.
The relatively low beta of 0.56 suggests GNLX is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, GNLX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Genelux Corporation's trajectory.